The 8 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 17.50, with a high estimate of 30.00 and a low estimate of 8.00. The median estimate represents a -33.71% decrease from the last price of 26.40.
The current consensus among 9 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since January, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.01
Reporting Date Nov 09
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.